000			03581nam a22003495i 4500
001			235413
003			ES-VaUE
005			20221220020703.0
007			cr nn 008mamaa
008			100301s2005 xxu| s |||| 0|eng d
020			_a9781592598540
024	7		_a10.1385/1592598544 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC
245	1	0	_aAntisense Therapeutics _cedited by M. Ian Phillips.
250			_a2nd edition 2005
264		1	_aTotowa, NJ _bHumana Press _c2005
300			_a1 recurso en línea (344 páginas) _b56 ilustraciones
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_aarchivo de texto _bPDF
490	0		_aMethods in Molecular Medicine _x1940-6037 _v106
505	0		_aAntisense Therapeutics -- Antisense Inhibition -- Cardiovascular -- Local Application of Antisense for Prevention of Restenosis -- Antisense Therapeutics for Hypertension -- Antisense Strategies for the Treatment of Heart Failure -- Cancer -- Clinical Studies of Antisense Oligonucleotides for Cancer Therapy -- Antisense Therapy in Clinical Oncology -- Radionuclide-Peptide Nucleic Acid in Diagnosis and Treatment of Pancreatic Cancer -- uppression of Pancreatic and Colon Cancer Cells by Antisense K-ras RNA Expression Vectors -- Induction of Tumor Cell Apoptosis and Chemosensitization by Antisense Strategies -- Utility of Antioncogene Ribozymes and Antisense Oligonucleotides in Reversing Drug Resistance -- Blood-Brain Barrier -- Transport of Antisense Across the Blood-Brain Barrier -- Dermal -- Transdermal Delivery of Antisense Oligonucletoides -- Drugs -- Antisense Strategies for Redirection of Drug Metabolism -- Gastrointestinal -- Antisense Oligonucleotide Treatment of Inflammatory Bowel Diseases -- Hepatitis -- Optimizing Electroporation Conditions for Intracellular Delivery of Morpholino Antisense Oligonucleotides Directed Against the Hepatitis C Virus Internal Ribosome Entry Site.
520			_aAnnouncement of the complete sequencing of the human genome in April 2003 demonstrated the presence of thousands of targets for antisense oligonucleotides and opened the way to hundreds of preclinical animal studies and some 20 ongoing clinical trials. In this second edition of Antisense Therapeutics, a team of leading researchers and clinical scientists demonstrate the new reality of antisense and RNA inhibition for treating a broad range of diseases. The authors show how antisense oligonucleotides are being designed and studied in relation to hypertension, various cancers, inflammatory bowel disease, brain disorders, the blood-brain barrier, and drug delivery. Highlights include RNA-based therapies for many diseases, up-to-date methods and applications, and insight into the enormous potential to provide a new generation of drugs. Highly practical and disease oriented, Antisense Therapeutics, Second Edition offers not only a primer for a new generation of drug discovery researchers, but also an illuminating exploration of the potential in exploiting RNA inhibition for novel human therapeutics.
700	1		_aPhillips, M. Ian _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9781617374210
776	0	8	_iPrinted edition: _z9781588292056
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1385/1592598544 _z(usuarios Universidad Europea de Valencia)
942			_2lcc _cLE
988			_aSpringer_Protocols_2005
999			_c235413 _d235413